Pharma and life sciences: R&D expensed, the USFDA pipeline, and price erosion

A pharmaceutical company spends years and fortunes discovering and developing drugs, builds a pipeline of products worth thousands of crores, and its balance sheet barely reflects any of it. It earns a fat margin selling branded medicines at home and a thin, shrinking margin selling generics into the United States — and reports the two blended into one number that flatters the weak part and hides the strong. And one morning a regulator on the other side of the world sends a letter, and a plant supplying a third of its revenue is suddenly at risk of being shut out of its biggest market. Pharma is a sector where the most important things — the research asset, the eroding US price, the regulatory risk — are the ones least visible in the ordinary financial statements. illustrative

Three features make it read differently from a normal manufacturer. First, research and development is expensed as incurred under Indian rules, not capitalised, so the years of research that build the pipeline never appear as an asset — the balance sheet understates the real investment, and return ratios look higher than the economics warrant. Second, the US generics business erodes by design: once a drug goes off-patent, competitors flood in and the price falls year after year, so a US-heavy firm is on a treadmill, launching new products just to replace the ones whose prices are collapsing. Third, the whole US business hangs on regulatory approval of specific manufacturing plants, and a single action by the USFDA — the United States Food and Drug Administration, the American drug regulator whose approval a company must have to sell medicines in the United States — can cut off a plant's access to that market overnight, a binary risk that appears in the accounts only after the revenue has vanished.

So this module reads a pharma company through what the financials obscure: the segment mix, because US generics and branded home sales are utterly different businesses blended into one margin; the R&D that is expensed, so the real asset sits off the balance sheet; the price erosion that means US revenue must be constantly replaced; and the USFDA pipeline and plant approvals, where the sector's defining risk lives. Applying the five-questions method, the top line splits by geography, the real asset is invisible, and the leading indicators are launches, filings and regulatory status — not the blended P&L.

The capitalisation module taught that whether a spend is expensed or capitalised changes reported profit and the asset base. Pharma is the sector where the largest and most valuable spend — research — is expensed, so the accounting systematically understates the business, and where two very different businesses hide inside one set of accounts. This module exists because reading a pharma company on its blended margin and its return ratios, as one would an ordinary manufacturer, misses the segment cross-currents, the invisible research asset, and the regulatory risk that actually drive it.

Three ideas carry it. R&D expensing is the treatment, under Indian accounting, of most drug research as a cost of the year rather than a capitalised asset — so a research-heavy firm's profit and asset base both read low, and its ROCE reads high, because the pipeline it is building never appears on the balance sheet. Price erosion is the structural decline in generic drug prices after patent expiry, as competitors enter — so US generics revenue falls in price year after year, and a firm must keep launching new products just to hold its revenue. And the USFDA pipeline is the set of pending product approvals — ANDAs, short for Abbreviated New Drug Applications, the filing a company makes to the USFDA for permission to sell a generic (a copy of an off-patent drug) in the US — and the regulatory status of the manufacturing plants, together the leading indicator of future US revenue and the location of the sector's binary risk.

Without this module, three errors follow. A reader admires a high ROCE without realising the research asset is expensed and the ratio inflated. A reader reads a stable blended margin without seeing that an eroding US generics business is being propped up by a strong branded one, or a one-off licensing deal masking decline. And a reader ignores the plant-level regulatory status until a USFDA action wipes out a slice of revenue. The point is to read the segments apart, to treat the R&D as the real (if invisible) investment, to watch launches against price erosion, and to hold the USFDA pipeline and plant approvals as the leading indicators and the key risk.

See the segment cross-currents and the expensed research first.

The segments are different businesses. A blended margin hides that US generics and branded home-market medicines are almost opposite economics. US generics earn a thin margin that erodes — the drug is off-patent, competitors undercut, the price falls, and the only defence is scale and constant new launches. Branded home-market medicines earn a fat, stable margin, because doctors prescribe by brand and patients stay loyal, so pricing holds. A firm that is 60% US generics and 40% branded is a very different, and more fragile, business than one with the reverse mix, even at the same blended margin. Reading the segment split — its size and its margin trajectory — is the first move.

R&D is expensed, so the real asset is invisible. Under Indian accounting most drug research is expensed as incurred rather than capitalised. That has two effects. It depresses reported profit and the asset base in the years of heavy research, so a firm investing in its pipeline looks less profitable and less capital-intensive than it is. And it inflates the return on capital employed, because the denominator — capital employed — excludes the research investment that is the firm's most valuable asset. So a high ROCE at a research-heavy pharma is partly an accounting artefact, and the real asset — the pipeline of drugs in development and the products approved but not yet launched — sits off the balance sheet entirely, read in the filings and the R&D disclosures, not the totals.

Price erosion is the treadmill. A generic drug's price falls structurally after patent expiry, so US generics revenue is always eroding on the existing products. A firm holds its revenue only by launching new generics — winning approval for the next drug coming off patent — fast enough to replace the erosion on the old ones. So US revenue growth is a race between new launches and price erosion, and a firm whose launches slow while erosion continues will see its US business shrink even as it looks busy. Reading the launch cadence against the erosion rate is how you judge whether the treadmill is being kept up.

The USFDA pipeline and plant risk. Two regulatory things drive a US-exposed pharma. The pipeline of pending approvals (ANDAs filed and awaiting clearance) is the leading indicator of future launches and revenue. And the regulatory status of the manufacturing plants is the binary risk: the USFDA inspects plants, and an adverse finding — a warning letter escalating to an import alert — can bar a plant's products from the US market until the issues are fixed, which can take years. Because a single plant often supplies a large share of the US revenue, that risk is concentrated and severe, and it appears in the financials only after the revenue is already lost. The plant status is not in the P&L; it is in the regulatory disclosures and the news flow, and it is one of the first things to check.

Pharma reads differently from an ordinary manufacturer in specific ways, and setting it beside its neighbours shows which.

The inversion is that pharma's most important asset and its most important risk are both largely absent from the financial statements. The research that builds the pipeline is expensed, so it is off the balance sheet, making the firm look less invested and more profitable on capital than it is; and the regulatory approval that gates the US revenue lives in inspection reports and import alerts, not in the accounts, so the risk crystallises in the numbers only after it has struck. A cement maker's assets and risks are on its balance sheet and in its market; a pharma firm's are in its filings, its R&D pipeline and a regulator's decisions. The reader must invert the instinct to read the statements as the business: for pharma, the statements are the visible residue of a business whose real drivers — the pipeline, the launch cadence, the plant status — sit outside them, and reading only the blended margin and the return ratios both flatters the weak segment and misses the risk that matters most.

Read the composite formulations exporter. Its blended picture looks solid — ₹9,800 crore of revenue at a healthy margin. But split the segments and the story changes. US generics are the largest slice at ₹5,400 crore of revenue but earn only a 12% EBIT margin (EBIT — earnings before interest and tax — is operating profit: what the business earns before financing costs and tax), under constant price erosion. The India branded business earns 28% on ₹3,100 crore — less than half the US revenue, but far more profitable and stable. Rest-of-world is ₹1,300 crore at 15%. So the blended margin is a mix of a big, thin, eroding engine and a smaller, fat, durable one, and the quality of the business sits in that mix: a shift toward branded lifts both the margin and the durability, while growing reliance on US generics does the opposite. illustrative

Now the invisible asset. The firm expenses ₹780 crore of R&D each year — a large sum, and the source of its future products — but none of it appears as an asset on the balance sheet. So its reported profit is struck after that ₹780 crore, understating the cash the mature business throws off, and its return on capital is flattered because the research investment is not in the capital base. A reader admiring a high ROCE here is partly admiring an accounting effect; the real question is whether the ₹780 crore of expensed research is producing a pipeline of approvals that will replace the eroding US products, which is read in the ANDA filings, not the return ratio.

Then the two US-specific reads. Price erosion means the ₹5,400 crore US book is falling in price on its existing products, so the firm must keep winning new generic approvals to hold that revenue — the launch cadence against the erosion rate is the thing to watch, and a slowdown in launches would shrink the US business quietly. And the plant risk is binary: if the USFDA issued a warning letter on the plant supplying most of that US revenue, and it escalated to an import alert, a large, high-margin slice of the business could be cut off for years, with nothing in the current financials to warn of it. The regulatory status of the plants and the pending pipeline are the leading indicators; the blended P&L is the lagging residue.

The habit to build: for a pharma company, always split the segments — US generics (eroding, thin) versus branded (stable, fat) versus rest-of-world — and read the mix and its direction, not the blended margin. Treat the expensed R&D as the real, invisible investment and discount the flattered ROCE. Watch the launch cadence against price erosion to see whether the US treadmill is being kept up. And read the USFDA pipeline for future revenue and the plant inspection status for the binary risk. The business a pharma firm actually is lives in its segments, its pipeline and its regulatory standing, and only its faint outline is in the financial statements.

Set the annual price erosion on the US base and the revenue the firm adds through new launches, then watch the US book over four years. When launches outpace erosion the book grows; when erosion wins it shrinks — even while the firm looks busy launching. The US generics business is a treadmill, a race between new approvals and the price falling on the old products, and this is the trade-off you are really reading.

The pipeline of filings tells you how many products are awaiting approval, but not whether they will be approved, when, or at what price. An ANDA can be delayed for years, approved into a market where three competitors got there first and the price has already collapsed, or rejected outright. So a large filing pipeline is a leading indicator with wide error bars, and its value depends on the quality and differentiation of the products in it — complex generics and first-to-file opportunities are worth far more than crowded, commodity molecules — which the count of filings does not capture. The pipeline points to potential revenue; the realisation depends on approval timing, competition and pricing that sit outside the number.

Nor can the financials price the regulatory risk before it strikes. A plant's inspection status can look clean right up until an adverse finding, and the market often cannot judge, from outside, how serious an observation is or whether it will escalate to an import alert. The risk is real, binary and concentrated, and it appears in the accounts only after the revenue is lost — so a firm can look financially healthy while carrying a plant risk that a single inspection could crystallise. Reading the inspection history and the concentration of revenue by plant helps size the exposure; it cannot forecast the regulator's next decision.

And the segment and pipeline reading cannot, on its own, judge the durability of the branded franchise or the threat of the next technology. A branded home-market business is durable only as long as the brands retain their prescription loyalty against new competition and any shift to a different treatment paradigm, and a whole category of drugs can be disrupted by a new class of medicine. The segment margins measure today's economics; whether the branded moat holds, and whether the firm's therapeutic areas are on the right side of medical progress, are judgements about competition and science that the accounts and the pipeline gesture at but do not settle.

How it comes up. When a pharma firm reports strong US numbers, a sharp analyst probes erosion and launches. The question sounds like this: "US revenue grew, but what was the price erosion on the base business, how many launches drove the growth, and is any of it a one-off like an out-licensing deal or a limited-competition opportunity?" The analyst is separating the durable treadmill from erosion masked by one-offs — such as an out-licensing deal, where the firm sells another company the rights to one of its drugs for an upfront payment that lifts this year's profit but does not recur.

A good answer, verbatim-style.

"Fair to break it down. Base price erosion was about high single digits, in line with the market. We offset it with eleven new launches, two of which were limited-competition and contributed outsized margin — I'd flag those as not fully repeatable. There was no out-licensing income this quarter. Underlying, ex the limited-competition products, US grew low single digits, and our pipeline has 40-odd ANDAs pending, including several complex generics we think are differentiated. On plants, our largest facility cleared its last inspection with zero observations."

It quantifies erosion, splits the growth into repeatable launches and one-offs, gives the pipeline quality, and volunteers the key plant's inspection status. It lets you judge the durable US trajectory and the risk.

An evasive answer, verbatim-style.

"We're pleased with our strong US performance, driven by our robust product portfolio and best-in-class execution. Our pipeline remains healthy and we continue to invest in R&D for the future. We're confident in our compliance culture and our relationships with regulators. Overall momentum across markets remains strong."

Cites "strong US performance" without the erosion rate, "robust portfolio" without splitting launches from one-offs, and "confident in our compliance culture" in place of the specific plant inspection status. It is exactly the answer a firm whose US growth was a one-off over an eroding base, or carrying an undisclosed plant issue, would give.

The follow-up nobody asks. "Excluding limited-competition and one-off products, what was the base US price erosion and the underlying growth, and what is the inspection status of each plant supplying more than 10% of US revenue?" That forces the durable trajectory and the concentrated regulatory risk into the open. Watch what happens when it is not asked. If "strong performance, healthy pipeline, good compliance culture" is allowed to stand, an investor credits a one-off-flattered number over an eroding base and misses a plant risk. The silence is the tell — either the underlying US business is eroding faster than it grows, or a plant carries an issue the firm would rather not detail.

The first trap is admiring a pharma firm's return ratios without adjusting for expensed R&D. Because research is expensed rather than capitalised, a research-heavy firm's profit and asset base both read low and its ROCE reads high — the return looks superb precisely because the most valuable investment, the pipeline, is not in the capital base. A reader who ranks pharma firms on ROCE, as they would manufacturers, rewards the accounting rather than the economics, and may prefer a firm that under-invests in research (and shows a higher ROCE) to one building a real pipeline. The research is the asset; the ratio that excludes it is misleading.

The second trap is reading a stable blended margin as a stable business. US generics and branded home sales blend into one margin, and a firm can hold that blended number while its mix deteriorates — the eroding US book growing as a share while the durable branded book shrinks, or a one-off out-licensing deal or a limited-competition product masking underlying erosion. The blended margin can look steady while the quality of the business falls, and only splitting the segments and stripping out the one-offs reveals whether the durable, high-margin branded engine is growing or being run down.

The third trap is ignoring the plant-level regulatory risk until it strikes. A pharma firm's US revenue hangs on the USFDA approval of specific plants, and that risk is binary, concentrated, and absent from the financials until the revenue is already gone. A firm can look financially pristine while a single plant — supplying a third of its US revenue — carries an issue that an import alert could crystallise, cutting off a large, high-margin slice of the business for years. A reader who reads only the accounts and never checks the inspection history and the revenue concentration by plant has ignored the sector's defining risk, and it is precisely the kind of risk that turns a quality compounder into a broken thesis overnight.